GoodRx Holdings, Inc.宣布，已在全国范围内超过7万家药房推出自费价格方案，显著提升患者对礼来公司新型口服GLP-1药物Foundayo™以及Zepbound® Kwikpen®的可及性。
这一举措旨在帮助消费者绕过传统保险流程，通过透明定价直接获取创新糖尿病与减重疗法。目前，自费购药服务已覆盖CVS、Walgreens等主流连锁药房及独立药店网络。
Foundayo作为首款口服GLP-1受体激动剂，与注射剂Zepbound的Kwikpen便携式给药装置共同构成了礼来的代谢疾病治疗矩阵。GoodRx通过其比价平台为患者提供实时价格对比，部分药房的自费成本可比保险自付额低30%以上。
行业分析师指出，此举可能重塑GLP-1药物市场格局——一方面缓解了保险覆盖不足患者的用药压力，另一方面也为礼来拓展了传统医保体系外的增量市场。随着诺和诺德等竞争对手加速布局口服制剂领域，便捷的支付渠道将成为药企商业化策略的关键变量。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.